Inventor · disambiguated record
Thomas Krahn
Also filed as: KRAHN THOMAS
19 granted patents·17 pending applications·362 citations·filing 1999–2015
95Inventor score
Top patents by PatentIndex Score
36 records- 0193US7109218B2Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the sameBAYER HEALTHCARE AG·Filed 2002·Granted Sep 19, 2006·61 cites·8 claims
- 0292US7709504B2Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomitingBAYER SCHERING PHARMA AG·Filed 2005·Granted May 4, 2010·27 cites·4 claims
- 0392US7078417B2Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparationsBAYER AG·Filed 2002·Granted Jul 18, 2006·59 cites·8 claims
- 0492US7045631B2Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligandsBAYER AG·Filed 2002·Granted May 16, 2006·53 cites·6 claims
- 0591US7129255B2Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptorBAYER AG·Filed 2002·Granted Oct 31, 2006·55 cites·6 claims
- 0688US7135486B1Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereofBAYER AG·Filed 2000·Granted Nov 14, 2006·35 cites·17 claims
- 0786US7855219B2Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereofBAYER SCHERING PHARMA AG·Filed 2002·Granted Dec 21, 2010·26 cites·5 claims
- 0883US8242281B2Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligandsROSENTRETER ULRICH·Filed 2006·Granted Aug 14, 2012·6 cites·5 claims
- 0982US7825255B2Adenosine receptor selective modulatorsBAYER SCHERING PHARMA AG·Filed 2002·Granted Nov 2, 2010·18 cites·5 claims
- 1080US8703696B2Dipeptoid prodrugs and the use thereofLERCHEN HANS-GEORG·Filed 2008·Granted Apr 22, 2014·3 cites·8 claims
- 1178US7504421B2Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their useROSENTRETER ULRICH·Filed 2006·Granted Mar 17, 2009·4 cites·13 claims
- 1274US8957017B2Dipeptoid prodrugs and their useBAYER IP GMBH·Filed 2014·Granted Feb 17, 2015·1 cites·7 claims
- 1371US7045544B2Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseasesBAYER HEALTHCARE AG·Filed 2002·Granted May 16, 2006·6 cites·7 claims
- 1466US6984642B1Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitorsBAYER AG·Filed 2000·Granted Jan 10, 2006·4 cites·21 claims
- 1561US6649616B2Substituted phenylcyclohexanecarboxamides and their useBAYER AG·Filed 2001·Granted Nov 18, 2003·1 cites·16 claims
- 1656US6649618B2Substituted amidoalkyl-uracils and their useBAYER AG·Filed 2001·Granted Nov 18, 2003·1 cites·11 claims
- 1756US2008306070A1Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory DisordersBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 1854US2013040992A1Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective LigandsBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 1953US2009221649A1Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damageBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 2052US2006217373A1Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the sameBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 2150US7074780B2Substituted phenylcyclohexanecarboxamides and their useBAYER AG·Filed 2003·Granted Jul 11, 2006·0 cites·16 claims
- 2250US2004162427A1Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligandsFiled 2002·Application pending·0 cites
- 2349US2012122820A1Prodrugs and the use thereofDIEDRICHS NICOLE·Filed 2008·Application pending·0 cites
- 2447US2009298822A1Use of Activators of Soluble Guanylate Cyclase for Treating Reperfusion DamageBAYER HEALTH CARE·Filed 2006·Application pending·0 cites
- 2547US2015133364A1Dipeptoid prodrugs and their useBAYER IP GMBH·Filed 2015·Application pending·0 cites
- 2643US2006183753A1Use of substituted 2,5-diamidoindoles for the treatment of urological diseasesBAYER HEALTHCARE AG·Filed 2003·Application pending·0 cites
- 2743US2010048641A1Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating DiseasesBAYER HEALTHCARE AG LAW AND PA·Filed 2007·Application pending·0 cites
- 2840US2005054637A1Substituted piperazine cyclohexane carboxilic acid amides and the use thereofFiled 2002·Application pending·0 cites
- 2940US2009221573A1Use of Activators of Soluble Guanylate Cyclase for Promoting Wound HealingBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3040US2005159431A1Substituted alkyl uracils and thereofBAYER HEALTHCARE AG·Filed 2003·Application pending·0 cites
- 3139US2009215769A1Use of soluble guanylate cyclase activators for the treatment of Raynaud's PhenomenonBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3239US2009286781A1Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung DiseasesBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3339US2010016305A1novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disordersBAYER HEALTHCARE AG·Filed 2006·Application pending·0 cites
- 3437US2004235830A1Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseasesFiled 2001·Application pending·0 cites
- 3533US7125995B2Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS)BAYER AG·Filed 2001·Granted Oct 24, 2006·0 cites·11 claims
- 3632US6291515B1Use of efomycinsBAYER AG·Filed 1999·Granted Sep 18, 2001·2 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Thomas Krahn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →